
Swissmedic Highlights Post-Market Surveillance Obligations for Legacy Devices
Swissmedic, the Swiss Agency for Therapeutic Products, has released findings from a recent focused action, underscoring the critical importance of robust Post-Market Surveillance (PMS) for all medical devices, including those classified as Legacy Devices (LDs). The review emphasizes that manufacturers must actively monitor the performance and safety of their devices throughout their lifecycle.
The Swissmedic review focused on Periodic Safety Update Reports (PSURs). These reports are crucial for proactively identifying potential risks and ensuring continued device safety and effectiveness.
Key Findings and Implications
The Swissmedic review highlighted several key areas needing improvement among manufacturers. While the specific details of these shortcomings are outlined in the full Swissmedic report, the agency is using the review to remind manufacturers of their obligations.
EU and Swiss Regulations Demand PMS for Legacy Devices
The announcement serves as a timely reminder that both European Union (EU) regulations and Swiss regulationsย requireย manufacturers to meet comprehensive PMS requirements for Legacy Devices. Despite these devices being on the market for some time, manufacturers are not exempt from the responsibility of actively monitoring their safety and performance. This includes:
- Systematic data collection:ย Gathering data from various sources, including user feedback, complaints, and scientific literature.
- Proactive risk assessment:ย Regularly evaluating potential risks associated with the device and taking appropriate corrective actions.
- Transparent reporting:ย Submitting timely and accurate PSURs to regulatory authorities.
Manufacturers who fail to meet these PMS requirements risk facing regulatory action, including device recalls and market withdrawals. Swissmedic emphasizes its commitment to ensuring patient safety and will continue to actively monitor compliance with PMS regulations.
Link to the Swissmedic Report: EN_Schwerpunktaktion_PSUR-final.pdf
Latest news
%20(1)-250x250.jpg&w=256&q=75)
MedNet EC-REP at MedTec Japan 2025 โ Meet Us at Booth 3303
We are pleased to announce our participation as an exhibitor at MedTec Japan 2025, one of Asiaโs leading trade shows for medical device design and manufacturing. The event will take place in Tokyo from April 9โ11, 2025.

EU Publishes Second Revision of MDCG 2023-3: Key Updates for Manufacturers
The European Commission has released the second revision of the MDCG 2023-3 guidance document in January 2025. This update includes important clarifications in line with Regulation (EU) 2024/1860

EU Commission Updates Guidance on SARS-CoV-2 Test Classification
The In Vitro Diagnostic (IVD) expert panel of the European Commission has released new scientific advice regarding SARS-CoV-2.

EU Initiative on Medical Devices and In-Vitro Diagnostics: A Targeted Evaluation
The European Commission has launched a public consultation as part of its targeted evaluation of the EU rules on medical devices and in-vitro diagnostics.

Meet Us at Arab Health 2025!
We are thrilled to announce that we will be attending Arab Health 2025, taking place from Monday, January 27, 2025, to Thursday, January 30, 2025, in Dubai.

MedNet EC-REP GmbH to Exhibit at MEDICA 2024 in Dรผsseldorf
We are excited to announce its participation at MEDICA 2024, the worldโs leading trade fair for the medical industry, taking place from November 11th to 14th in Dรผsseldorf, Germany.
-250x250.jpg&w=256&q=75)
MedNet EC-REP GmbH Successfully Renews ISO 13485:2016 Certification
We are pleased to announce that MedNet EC-REP GmbH has successfully renewed its ISO 13485:2016 certification.